We believe synthetic DNA is approaching an inflection point in industry adoption, creating an opportunity for companies such as 4basebio to establish themselves as critical upstream suppliers of high-value DNA starting materials supporting next-generation therapeutic modalities. Recent transformational milestones at 4basebio reinforce this view, including the clinical progression of customer programmes utilising its synthetic DNA and the receipt of GMP certification (Good Manufacturing Practice) ....
